Clinical Trial to Evaluate the Safety and Efficacy of NTCB01-1 in Patients Who Require Parenteral Nutrition
- Conditions
- Parenteral Nutrition
- Interventions
- Drug: NTCB01-1Drug: NTCB-P
- Registration Number
- NCT06625931
- Lead Sponsor
- Yuhan Corporation
- Brief Summary
A Randomized, Open-labeled, Multi-center, Active-controlled, Parallel-group Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of NTCB01-1 versus NTCB-P in patients who require parenteral nutrition
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 60
- Those who are 19 years old or older at the screening visit
- Patients are expected to require PN for more than 3 days
- Patients who voluntarily signed the consent form
- Patients are expected difficult to survive more than 3 days
- Patients BMI is over 30 kg/m2
- Patients having hypersensitivity to any peanut-, fish-, soy-, egg protein, or investigational drug
- Patients with difficult peripheral intravenous line
- Patients judged to be unsuitable for this trial by investigators
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description NTCB01-1 NTCB01-1 - NTCB-P NTCB-P -
- Primary Outcome Measures
Name Time Method Occurance rate of adverse drug reaction Day 1 to day 4
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (7)
Keimyung University Dongsan Hospital
🇰🇷Daegu, Dalseo-gu, Korea, Republic of
Seoul Metropolitan Government Seoul National University Boramae Medical Center
🇰🇷Seoul, Dongjak-gu, Korea, Republic of
Seoul National University Hospital
🇰🇷Seoul, Jongno-gu, Korea, Republic of
Kosin University Gospel Hospital
🇰🇷Busan, Seo-gu, Korea, Republic of
The Catholic University of Korea, Seoul ST. Mary's Hospital
🇰🇷Seoul, Seocho-Gu, Korea, Republic of
Korea University Anam Hospital
🇰🇷Seoul, Seongbuk-gu, Korea, Republic of
Ajou University Medical Center
🇰🇷Gyeonggi-do, Suwon-si, Korea, Republic of